Unexploited opportunities for phage therapy

Frontiers in Pharmacology

Volumn 6, Issue SEP, 2015, Pages

  Oliveira, Hugo ^a   Sillankorva, Sanna ^a   Merabishvili, Maia ^b   Kluskens, Leon D ^a   Azeredo, Joana ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Antibiotic resistance; Bacterial pathogens; Bacteriophage therapy; Infectious diseases; Novel lytic bacteriophages

Indexed keywords

ANTIBIOTIC AGENT; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ISOLATION; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL INFECTION; GROWTH INHIBITION; HUMAN; NONHUMAN; NOTE; RESPIRATORY TRACT INFECTION; SEPTICEMIA; SKIN INFECTION; UROGENITAL TRACT INFECTION; WOUND INFECTION;

EID: 84944715100     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00180     Document Type: Note

References (25)

1. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12. doi: 10.1086/595011
2. Brüssow, H., and Hendrix, R. W. (2002). Phage genomics: small is beautiful. Cell 108, 13-16. doi: 10.1016/S0092-8674(01)00637-7
3. Callaway, T. R., Edrington, T. S., Brabban, A. D., Anderson, R. C., Rossman, M. L., Engler, M. J., et al. (2008). Bacteriophage isolated from feedlot cattle can reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts. Foodborne Pathog. Dis. 5, 183-191. doi: 10.1089/fpd.2007.0057
4. Chacko, R. T., Ventura, J., Zhuang, J., and Thayumanavan, S. (2012). Polymer nanogels: a versatile nanoscopic drug delivery platform. Adv. Drug Deliv. Rev. 64, 836-851. doi: 10.1016/j.addr.2012.02.002
5. El-Tahawy, A. T. (2004). The crisis of antibiotic-resistance in bacteria. Saudi Med. J. 25, 837-842.
6. FDA. (2006). Federal Register 47729-Approval of Listeria-specific Bacteriophage Preparation on Ready-to-Eat (RTE) Meat and Poultry Products. Rockville, MD. Available online at: http://www.fda.gov/OHRMS/DOCKETS/98fr/E6-13621.pdf
7. Health Safety Executive. (2013). The Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. London. Available online at: http://www.hse.gov.uk/pubns/misc208.pdf
8. Housby, J. N., and Mann, N. H. (2009). Phage therapy. Drug Discov. Today 14, 536-540. doi: 10.1016/j.drudis.2009.03.006
9. Joly-Guillou, M. L. (2005). Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11, 868-873. doi: 10.1111/j.1469-0691.2005.01227.x
10. Loc-Carrillo, C., and Abedon, S. T. (2011). Pros and cons of phage therapy. Bacteriophage 1, 111-114. doi: 10.4161/bact.1.2.14590
11. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miedzybrodzki, R., Klak, M., Fortuna, W., et al. (2014). Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295-304. doi: 10.1089/vim.2013.0128
12. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:e4944. doi: 10.1371/journal.pone.0004944
13. Pirnay, J. P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., et al. (2010). The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28, 934-937. doi: 10.1007/s11095-010-0313-5
14. Rice, L. B. (2009). The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12, 476-481. doi: 10.1016/j.mib.2009.08.001
15. Rohwer, F. (2003). Global phage diversity. Cell 113, 141. doi: 10.1016/S0092-8674(03)00276-9
16. Ryan, E. M., Gorman, S. P., Donnelly, R. F., and Gilmore, B. F. (2011). Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253-1264. doi: 10.1111/j.2042-7158.2011.01324.x
17. Sillankorva, S. M., Oliveira, H., and Azeredo, J. (2012). Bacteriophages and their role in food safety. Int. J. Microbiol. 2012, 863945. doi: 10.1155/2012/863945
18. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
19. Summers, W. C. (2001). Bacteriophage therapy. Annu. Rev. Microbiol. 55, 437-451. doi: 10.1146/annurev.micro.55.1.437
20. Summers, W. C. (2005). Bacteriophage Research: Early History. Bacteriophages: Biology and Applications. Boca Raton: CRC Press. 5-27.
21. Thiel, K. (2004). Old dogma, new tricks-21st Century phage therapy. Nat. Biotechnol. 22, 31-36. doi: 10.1038/nbt0104-31
22. Trigo, G., Martins, T. G., Fraga, A. G., Longatto-Filho, A., Castro, A. G., Azeredo, J., et al. (2013). Phage therapy is effective against infection by mycobacterium ulcerans in a murine footpad model. PLoS Negl. Trop. Dis. 7:e2183. doi: 10.1371/journal.pntd.0002183
23. Verbeken, G., Pirnay, J. P., Lavigne, R., Jennes, S., De Vos, D., Casteels, M., et al. (2014). Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immunol. Ther. Exp. (Warsz). 62, 117-129. doi: 10.1007/s00005-014-0269-y
24. Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A., Dolan, J. W., Schmidt, M. G., et al. (2003). Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47, 1301-1307. doi: 10.1128/AAC.47.4.1301-1307.2003
25. World Medical Association. (1964/2013). Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: World Medical Association.